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ThermostabilitySmoothened is a member of the G-protein coupled receptor (GPCR) family responsible for the transduction
of the Hedgehog signal to the intracellular effectors of the Hedgehog signaling pathway. Aberrant regulation
of this receptor is implicated in many cancers but also in neurodegenerative disorders. Despite the
pharmacological relevance of this receptor, very little is known about its functional mechanism and its
physiological ligand. In order to characterize this receptor for basic and pharmacological interests, we
developed the expression of human Smoothened in the yeast Saccharomyces cerevisiae and Smoothened was
then puriﬁed. Using Surface Plasmon Resonance technology, we showed that human Smoothened was in a
native conformational state and able to interact with its antagonist, the cyclopamine, both at the yeast
plasma membrane and after puriﬁcation. Thermostability assays on puriﬁed human Smoothened showed
that this GPCR is relatively stable in the classical detergent dodecyl-β-D-maltoside (DDM). The ﬂuorinated
surfactant C8F17TAC, which has been proposed to be less aggressive towards membrane proteins than
classical detergents, increased Smoothened thermostability in solution. Moreover, the replacement of a
glycine by an arginine in the third intracellular loop of Smoothened coupled to the use of the ﬂuorinated
surfactant C8F17TAC during the mutant puriﬁcation increased Smoothened thermostability even more. These
data will be very useful for future crystallization assays and structural characterization of the human receptor
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G-protein coupled receptors (GPCRs) are transmembrane proteins
that mediate most of their intracellular actions through pathways
involving activation of G-proteins and arrestin [1,2]. G-proteins
transmit intracellular signals to effector proteins such as enzymes
and ion channels, resulting in rapid changes in the concentration of
intracellular signaling molecules, cAMP, cGMP, inositol phosphates,
diacylglycerol, arachidonic acid, and cytosolic ions [3,4]. The super-
family of GPCRs comprises receptors for many hormones, paracrines
(local hormones), neurotransmitters, and neuromodulators with
important physiological functions. GPCRs represent about 30% of
current drug targets and their dysfunction causes many human
diseases. In the GPCR database [5], GPCRs are divided into six classes.
These are the Class A Rhodopsin-like receptors, which account for
over 80% of all GPCRs, Class B Secretin-like receptors, Class C
Metabotropic glutamate receptors, Class D Pheromone receptors,Class E cAMP receptors and the Class F Frizzled/Smoothened family.
This latter class comprises Frizzled and Smoothened receptors, which
are key regulators of animal development that signal through theWnt
and Hedgehog signaling pathways, respectively. The Hedgehog (Hh)
signaling pathway regulates body patterning and organ development
during embryogenesis. In adults, the Hh pathway is mainly quiescent,
with the exception of roles in tissue maintenance and repair, and its
inappropriate reactivation has been linked to several disparate human
cancers such as basal cell carcinomas and medulloblastomas [6]. The
Hh pathway involves two integral membrane proteins, Patched (Ptc)
and Smoothened (Smo). Ptc, a 12-transmembrane domain protein, is
the receptor of the secreted protein Hedgehog (Hh). In the absence of
Hh, Ptc inhibits the activity of Smo through an unknown mechanism.
Hh binding to Ptc releases Smo inhibition. Activated Smo is stabilized
on the plasma membrane and transduces the Hh signal to the
intracellular components of the pathway, culminating in the activa-
tion of the transcription factor Gli in mammals or Ci in Drosophila.
Despite the important pharmacological interest of this receptor, very
little is known about its functional mechanism or its physiological
ligand and partners in mammals [7].
In order to better understand signaling via Smo in mammals,
structural data are essential. Smo, like many other GPCRs, is present in
very low amounts in native sources. In order to undergo biochemical
and structural characterization, we over expressed this receptor in
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puriﬁed proteins provide a starting point for biochemical, biophysical
and structural studies, but the lack of sufﬁcient quantities of
functional and stable membrane proteins is frequently a bottleneck
hindering such studies. Recurring problems include i) recovering
adequate amounts of functional protein from the heterologous
expression system used, ii) solubilizing and purifying these proteins,
iii) maintaining stability and functionality in solution after extraction
from membranes and puriﬁcation.
We show in the present study that human Smo could be expressed
in the plasma membrane of the yeast Saccharomyces cerevisiae
and puriﬁed in a native and stable conformation, as assessed by
antagonist-binding and Surface Plasmon Resonance studies. Our
results indicate that human Smo is relatively stable in solution with
the classical detergent dodecyl-β-D-maltoside (DDM), and that the
ﬂuorinated surfactant C8F17TAC increases Smo thermostability in
solution. We also observed a synergistic effect of the ﬂuorinated
surfactant C8F17TAC and the replacement of a glycine by an arginine in
the Smo third intracellular loop on the receptor thermostability.
2. Materials and methods
2.1. Construction of expression vectors
For expression in S. cerevisiae, the cDNAs from human Smo and a
mutant form of human Smo in which the guanine in position 1303
was replaced by an adenine (giving the mutation G435R in the poly-
peptide sequence) were inserted in the YEpPMA-MAP vector contain-
ing the constitutive plasma membrane proton ATPase promoter
and the Multitag Afﬁnity Puriﬁcation sequence as described in [8],
giving the expression vectors YEpPMA-hSmo-MAP and YEpPMA-
hSmoG435R-MAP respectively.
For expression inDrosophila Schneider 2 cells, thewild type and the
mutant human Smo cDNAs were inserted in the pAc-MAP vector
containing the strong constitutive actine promoter and the Multitag
Afﬁnity Puriﬁcation sequence as described in [9], giving the expression
vectors pAc-hSmo-MAP and pAC-hSmo-G435R-MAP respectively.
2.2. Yeast culture
S. cerevisiae strain K699 (Mata, ura3, and leu 2–3), which was
generously given by R. Arkowitz, was transformed with YEpPMA-
hSmo-MAP or YEpPMA-hSmo-G435R-MAP expression vector by the
lithium acetate procedure [10] and grown on plates containing
minimal medium and an amino-acid mixture lacking leucine. Clones
were grown at 30 °C to an OD600 of 2 in minimal medium (0.67% yeast
nitrogen base without amino acids, 0.3 mM adenine, 0.5 mM uracil,
0.3 mM tyrosine and an amino acid mixture lacking leucine)
supplemented with 2% D-glucose. Yeasts were diluted to an OD600 of
0.1 in complete YEP medium (1.1% yeast extract, 2.2% bactopeptone,
0.3 mM adenine) supplemented with 2% D-glucose, grown at 18 °C
under 200 rpm shaking until the OD600 was 7, and centrifuged for
10 min at 2000 g and 4 °C (see detailed protocol in [11].
Large-scale production of hSmo-MAP was carried out in a 40-L
fermentor (BIOSTAT C-PLUS Sartorius BBI Systems, Unité de fermen-
tation IMM/IFR88 CNRS Marseille France). One liter of yeast with an
OD600 of 1.5 served to inoculate 30 L of YEP medium. Yeasts were
grown at 18 °C for 24 h (2.5 OD600) under 200 rpm shaking with 30 L
of air perminute. The culturewas then oxygenated with 45 L of air per
minute, kept for 6 h at 18 °C and 250 rpm shaking until the OD600 was
7, and centrifuged in a Sharples AS16 centrifuge (100 L/h).
2.3. Yeast membrane preparation
All steps were performed at 4 °C. Yeast cells were washed in cold
water, re-suspended in ice-cold disintegration buffer (50 mM Tris–HCl [pH 7.4], 500 mM NaCl, 2.5 mM EDTA, 4 mM Benzamidine and
1 mM PMSF), and broken with glass beads (425–600 μm, Sigma) for
15 min in a shaker at 2000 rpm (Heidolph Multi Reax shaker).
Unbroken cells and nuclei were pelleted for 10 min at 3000 g and
crude extract was obtained from the supernatant. Plasma membranes
were prepared by centrifugation of crude extract for 1 h at 18,000 g.
The membrane fraction was then washed twice with puriﬁcation
buffer (50 mM Tris–HCl pH (7.4), 500 mM NaCl, 10% glycerol, 4 mM
Benzamidine and 1 mM PMSF). Finally, the membrane fraction was
re-suspended in puriﬁcation buffer and frozen at −80 °C (for a
detailed protocol, see [11]).
2.4. Solubilization and puriﬁcation
Membrane fractions were thawed and simultaneously diluted to
3 mg/mL with ice-cold puriﬁcation buffer supplemented with 20 mM
of the non-ionic detergent DDM (dodecyl-β-D-maltoside,
CMC=0.15 mM). Solubilization of hSmo from the membrane was
performed at 4 °C with gentle agitation for 1 h. The solution was
centrifuged at 100,000 g for 1 h to pellet unsolubilized material. For
SPR experiments, Smo-MAPwas puriﬁed on a calmodulin column. The
supernatant containing solubilized hSmo was incubated with a pre-
equilibrated calmodulin column in the presence of 2 mM CaCl2
overnight at 4 °C on a rotating wheel. Non-speciﬁcally bound material
was removed from the resin with several washes with puriﬁcation
buffer supplemented with 2 mM DDM and 2 mM CaCl2. In order to
exchange DDM with the ﬂuorinated surfactants C6F13C2H4-S-poly-
Tris-(hydroxymethyl) aminomethane (C6F13TAC) (CMC=0.3 mM),
or C8F17C2H4-S-poly-Tris-(hydroxymethyl) aminomethane
(C8F17TAC) (CMC=0.03 mM) [12,13], the resin was washed 3 times
with 5-column volumes of puriﬁcation buffer supplemented with
2 mMCaCl2 and either 2 mMC6F13TAC or 2 mMC8F17TAC. Elutionwas
carried out with puriﬁcation buffer supplemented with 5 mM EGTA
and the appropriate surfactant. Aliquots were collected throughout
the puriﬁcation process, and analyzed by western-blot. For mass
spectrometry analysis, hSmoG435R-MAP was puriﬁed on Ni/NTA
agarose (Qiagen) and on Streptavidin sepharose (Amersham). The
solubilized fraction supplemented with 10 mM imidazole was
incubated overnight at 4 °C on Ni/NTA resin equilibrated with
puriﬁcation buffer containing 2 mM of DDM and 10 mM of imidazole.
The column was washed 3 times with puriﬁcation buffer containing
50 mM of imidazole, and hSmoG435R-MAP was eluted with a buffer
containing 400 mM of imidazole. Eluted fractions were pooled and
loaded on the streptavidin column, for 1 h at 4 °C. Finally,
hSmoG435R-MAP was eluted and loaded on SDS-PAGE for western-
blotting and Coomassie blue staining. The band corresponding to
hSmoG435R-MAP was cut and analyzed by mass spectrometry
(MALDI-TOF-TOF 4800 Applied Biosystems, IPMC Sophia Antipolis).
2.5. MAP peptide expression and puriﬁcation
The MAP sequence was inserted into the XhoI and NheI restriction
sites of the pBAD vector containing the inducible arabinose promoter
(kind gift from P. Demange). The Escherichia coli strain MC1061 was
transformed with the vector pBAD-MAP. Bacteria were grown in LB
medium supplemented with ampicillin at 37 °C. At an OD600 of 0.8,
0.4% of L-arabinose was added to the culture for 4 h at 37 °C to induce
MAP peptide expression. The bacteria were then centrifuged and the
pellet was washed with ice-cold water and then with ice-cold PBS
buffer supplemented with 1 mM PMSF and 4 mM Benzamidine. The
bacteria were sonicated for 5 min and centrifuged. CaCl2 was then
added to the supernatant to a ﬁnal concentration of 2 mM prior to
incubation for 1 h with calmodulin resin pre-equilibrated in PBS
buffer supplemented with 1 mM PMSF, 4 mM benzamidine and 2 mM
CaCl2. After several washes with equilibration buffer, theMAP peptide
was eluted with PBS buffer supplemented with 1 mM PMSF, 4 mM
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standard to quantify hSmo-MAP.
2.6. Protein quantiﬁcation
The proteins were quantiﬁed using the Bio-Rad protein assay.
2.7. SDS-PAGE and western-blotting
Protein samples were separated on SDS-PAGE (acrylamide/bis-
acrylamide: 8% for hSmo-MAP or hSmoG435R-MAP and 15% for MAP
peptide). For western-blot analysis, gels were transferred to nitrocel-
lulose using standard techniques. Blots were ﬁrst incubated for 1 h at
room temperature in the blocking buffer (20 mM Tris–HCl (pH 7.4),
450 mM NaCl, 0.1% Tween-20 supplemented with 4% non-fat milk)
and probed overnight at 4 °C with monoclonal mouse anti-HA anti-
bodies (laboratory-made, dilution 1:20). The blots were then washed
three times in the blocking buffer. Secondary polyclonal goat anti-
mouse immunoglobulins coupled to horseradish peroxidase (Dako)
(dilution 1:5000) were then applied for 2 h at 4 °C. Revelation was
carried out using ECL kit (Amersham Biosciences), a CCD camera and
the Las 3000 system® (Fuji).
2.8. Native gel
Protein samples were separated on native gel under non-
denaturing conditions in which acrylamide gels, running, loading
and transfer buffers lacked SDS. The gels were then transferred to
nitrocellulose membrane and probed with anti-HA antibodies.
2.9. Fluorescent ligand binding measurements
100 µg of membrane preparation were incubated in PBS buffer and
increasing concentrations of Bodipy-cyclopamine (Bo-CPN) (between 0
and 25 nM) 4 h at RT, centrifuged for 1 h at 25,000 g and re-suspended
in 1 mL of PBS buffer. The ﬂuorescence measurements were realized on
a spectroﬂuorimeter SAFAS FLX-Xenius. Theﬂuorescence variationsΔF/
Fwere calculated for each concentration of Bo-CPN and analyzed using
Origin software. The Bo-CPN standard curve was realized bymeasuring
the ﬂuorescence variations before centrifugation.
2.10. Surface plasmon resonance (SPR) experiments
SPR experiments were performed on a Biacore 3000 (Biacore/GE
Healthcare Uppsala, Sweden) with a CM5 sensor chip from Biacore/
GE Healthcare. A stock solution of N-(2-Aminoethyl) cyclopamine in
DMSO (5 mg/mL) was prepared and diluted 1:10 in sodium acetate
buffer pH 5.5 for covalent amine-coupling to the CM5 sensor chip.
Flow cell 2 (Fc2) was activated with 200 mM N-ethyl-N-(3-dimethy-
laminopropyl)-carbodiimide (EDC) and 50 mM N-hydroxysuccini-
mide (NHS), and 100 μL (50 µg) of N-(2-Aminoethyl) cyclopamine
were injected at 10 μL/min. The surface was deactivated with
ethanolamine. Flow cell 1 (Fc1) was activated and deactivated, and
used as a reference ﬂow cell. The surfaces were then washed with
three pulses of 50 mM NaOH (15 μL at 5 μL/min).
Experiments on membrane preparations were carried out at 25 °C.
50 µL of membrane preparation from hSmo-expressing yeasts or from
yeasts that do not express hSmo, were diluted in HBS-N running
buffer (10 mM HEPES (pH 7.4) and 150 mM NaCl, GE Healthcare) at
100 µg/mL and injected over both the reference (Fc1) and the CPN-
coupled (Fc2) ﬂow cells at a ﬂow rate of 5 µL/min. The difference
between sensorgrams recorded on Fc2 and Fc1 was reported. The
sensor chip surfacewas regenerated twicewith 10 μL of 50 mMNaOH,
0.05% SDS at 20 μL/min.
Experiments on puriﬁed hSmo were performed at 10 °C. Puriﬁca-
tion buffer containing 2 mM of surfactant was used as a runningbuffer, otherwise the speciﬁc buffer was stated. 40 μL (80 ng) of
puriﬁed hSmowere injected on both the reference (Fc1) and the CPN-
coupled (Fc2) ﬂow cells at a ﬂow rate of 10 μL/min. The difference
between the sensorgrams recorded on Fc2 and Fc1 was reported. The
sensor chip surfacewas regenerated twicewith 10 μL of 50 mMNaOH,
0.05% SDS at 20 μL/min.
To determine the stability of hSmo in surfactants over time,
puriﬁed hSmo fractionswere stored at 4 °C and bindingwasmeasured
10, 20 and 30 days after puriﬁcation. The percentages of remaining
binding compared to initial binding measured 1 day after puriﬁcation
were calculated from at least two independent experiments.
For thermostability assays, sensorgrams were recorded after
incubating puriﬁed Smo for 30 min at temperatures ranging from 4
to 70 °C prior to injection on the reference (Fc1) and the CPN-coupled
(Fc2) ﬂow cells at a ﬂow rate of 10 μL/min. The percentage of re-
maining binding after incubation was determined with respect to its
own unheated control. In order to determine the inﬂection point
of the melting curves, which was assumed to equal the melting
temperature (Tm), a Boltzmann sigmoid equation was ﬁtted to the
raw data with the Origin software.
To determine the kinetic constants of the CPN-Smo binding, Fc2, 3
and 4 of a new CM5 sensor chip were coupled with different amounts
of N-(2-Aminoethyl) cyclopamine, Fc1 being the reference ﬂow cell.
Increasing concentrations of puriﬁed Smo were injected onto the four
ﬂow cells and the differences between the sensorgrams recorded on
each CPN-coupled ﬂow cell and Fc1 were reported and analyzed using
BiaEva software.
2.11. Surface Immunoﬂuorescent labeling of Drosophila Schneider 2 cells
S2 cells were cultured and transiently transfected with 0.5 μg of
pAc-hSmo-MAP or pAc-hSmo-G435R-MAP as described in [9]. Three
days after transfection, the cells were treated or not with Hh-
conditioned medium, and cell surface labeling was performed as
described in [9] by incubating cells on ice for 1 h with a rabbit
polyclonal antibody raised against amino acids 488–787 of human
Smo (1:100; N-300; Santa Cruz Biotechnology) in S2 medium
containing 10% of fetal bovine serum. After dilution and centrifuga-
tion, the cells were incubated on ice for 30 min with a rhodamine
ﬂuorescent secondary antibody (Alexa 568 goat anti-rabbit IgG
(1:500; Molecular Probes)) in S2 medium containing 10% of fetal
bovine serum. After dilution and centrifugation, the cells were re-
suspended in phosphate-buffered saline plus 1% formaldehyde.
Rhodamine ﬂuorescence was analyzed by ﬂuorescence microscopy
and image acquisition was performed using a confocal system (Zeiss
LSM510 Meta) with an objective Plan Apochromat ×63/1.4 oil
differential interference contrast. Cell ﬂuorescence was analyzed
using Image J software.
3. Results
3.1. Expression, optimization and large-scale production of
human Smoothened
Human Smoothenedwas expressed in the yeast S. cerevisiaewith a
multitag afﬁnity puriﬁcation sequence of 165 amino acids fused at its
C-terminus (hSmo-MAP, Fig. 1A) allowing detection of hSmo by
western-blotting using antibodies directed against the hemagglutinin
(HA) tag, and puriﬁcation of hSmo using three afﬁnity resins
(calmodulin, streptavidin, Ni–NTA), as already described in [8].
Expression of hSmo-MAP was improved and subsequently scaled
up.We evaluated the impact of aeration on the hSmo-MAP expression
level by growing the yeast cells with different medium/air volume
ratios of 1/10, 1/7, 1/5 and 1/4 in a 2-L ﬂask. Yeasts were grown until
the OD600 was 7 and plasmamembranes were prepared. Expression of
hSmo-MAP in each culture condition was checked by western-blot
Fig. 1. Expression of human Smoothened in S. cerevisiae. A. MAP sequence fused at hSmo C-terminus. The MAP sequence is composed of 165 amino acids: three afﬁnity puriﬁcation
tags (a calmodulin binding domain (CBD), a streptavidin tag and a hexa-histidine tag), the hemagglutin A epitope, and cleavage sites for factor Xa, TEV and thrombin. B. Effect of the
yeast culture oxygenation on hSmo-MAP expression level. Western-blot with plasma membrane preparations from S. cerevisiae expressing hSmo-MAP cultured with indicated
medium/air ratio (v/v): 1/10 (lane 1), 1/7 (lane 2), 1/5 (lane 3) and 1/4 (lane 4) (respectively 200 mL, 300 mL, 400 mL and 500 mL of YEPmedium in a 2-L ﬂask). Samples were run
on SDS-PAGE, transferred to a nitrocellulose membrane and probed with anti-HA antibodies. C. Large-scale production of hSmo-MAP in a 40-L fermentor. Plasma membranes were
prepared from hSmo-MAP-expressing yeast grown in 2-L ﬂasks (lane 1) or in 40-L fermentors (lane 2). 40 μg of membranes were loaded on SDS-PAGE, western-blotted and probed
with anti-HA antibodies.
Fig. 2. Quantiﬁcation of human Smoothened expression using the MAP peptide as a
standard. MAP was expressed in E. coli and puriﬁed on calmodulin resin. Different
quantities of puriﬁed MAP peptide (lane 1: 10 ng, lane 2: 25 ng, lane 3: 50 ng, lane 4:
100 ng, lane 5: 200 ng) and 5 μg of membrane fraction from yeast expressing hSmo-
MAP (lane 6) were loaded on SDS-PAGE, transferred to a membrane and probed with
anti-HA antibodies. The intensities of the bands corresponding to theMAP peptide were
estimated by densitometry using the ImageJ software and used to draw the MAP
standard curve. The intensity of hSmo-MAP band was reported on this standard curve
to estimate the quantity of hSmo-MAP produced.
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the predicted size of hSmo-MAP (100 kDa) and a weaker band around
65 kDa. The highest expression level of hSmo-MAP was obtained in
the higher oxygenation conditions (medium/air volume ratios of 1/
10 and 1/7). We used the ratio 1/7 for yeast cultures grown in ﬂasks.
This experiment allowed air/volume adaptation in the 40-L fermentor
for hSmo-MAP scale-up production. Western-blot analysis (Fig. 1C)
shows that the quantity of hSmo-MAP expressed at the yeast plasma
membrane was comparable in 2-L ﬂask and 40-L fermentor cultures.
To quantify the amounts of hSmo-MAP expressed on the yeast
plasma membrane, the production of the MAP tag alone was neces-
sary. Therefore we carried out the expression of the MAP peptide in E.
coli and the peptide was then puriﬁed using calmodulin afﬁnity resin.
Puriﬁed MAP peptide was used as a standard to quantify hSmo-MAP
on western-blots with anti-HA antibodies (Fig. 2). The expression
level of hSmo-MAPwas estimated at about 50 pmol/mg of membrane
protein, which in mass represents 150 μg of hSmo-MAP per liter of
yeast culture. However, due to the fact that the transfer of the
hydrophobic protein hSmo-MAP was surely less efﬁcient than that of
the soluble peptide MAP, this value could have been underestimated.
3.2. Antagonist-binding properties of Smoothened expressed on the yeast
plasma membrane
In order to ﬁnd out if hSmo-MAP was expressed in S. cerevisiae
in a native conformation, its ability to interact with its antagonist
cyclopamine (CPN) was measured.
Binding experiments using a ﬂuorescent derivative of the
cyclopamine, the Bodipy-cyclopamine (Bo-CPN) (Fig. 3A) were
carried out on membrane prepared from yeast expressing hSmo-
MAP and control yeast. The ﬂuorescence variations associated with
hSmo-MAP-containing membranes as a function of the concentration
of Bo-CPN allowed the calculation of apparent KD values between
1.7 nM and 5.7 nM, and of the number of active hSmo-MAP per mg of
membrane proteins between 20 and 50 pmol depending on mem-
brane preparation (Fig. 3A).
Biacore surface plasmon resonance (SPR) technology forms the
basis of a rapid and reliable automated biosensor system and allows
real-time detection of binding without labeling [14]. One of the
binding partners is immobilized on the sensor chip surface and the
other is passed over it in solution. Binding causes a change in the
refractive index at the biosensor surface which is transformed into a
Fig. 3. Smoothened expressed on the yeast plasma membrane bound to its antagonist,
cyclopamine. A. Fluorescent-cyclopamine-binding assay. 100 µg of membrane prepa-
ration from yeast expressing hSmo-MAP were incubated with increasing concentra-
tions of Bodipy-cyclopamine (Bo-CPN, structure shown), centrifuged, re-resuspended
in PBS, and ﬂuorescence emission was recorded at 520 nm (ex. 490 nm). Fluorescence
variations (ΔF/F) were plotted as a function of the Bo-CPN concentration. The apparent
KD and the number of active hSmo-MAP were calculated using Origin software.
B. Surface plasmon resonance experiments. An amine-derivative of the cyclopamine
(N-(2-Aminoethyl) cyclopamine, structure shown) was covalently coupled to the ﬂow
cell Fc2 of a Biacore CM5 sensor chip. The sensorgrams presented are the difference
between signals recorded on the CPN-coupled ﬂow cell Fc2 and on the reference ﬂow
cell. 50 μL of membrane fraction (100 μg/mL) from control yeasts that do not express
hSmo (sensorgram A), from 2 L ﬂask-cultured yeast expressing hSmo-MAP (sensor-
gram B), and from fermentor-cultured yeast expressing hSmo-MAP (sensorgram C),
were injected over both Fc1 and Fc2.
Fig. 4. Silver stained SDS-PAGE of puriﬁed hSmo-MAP. hSmo-MAP was puriﬁed on
calmoduline resin followed by Ni–NTA resin. Puriﬁed hSmo-MAP was loaded on an 8%
SDS-PAGE and silver stained.
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resonance units (RU) on the recorded sensorgram. An amine-
derivative of CPN, N-(2-aminoethyl) cyclopamine (Fig. 3B) was
covalently immobilized by amine-coupling on the ﬂow cell 2 (Fc2)
of a CM5 sensor chip producing a change of the refractive index of the
Fc2 surface of 3600 RU. Membrane preparations from yeast that do or
do not express hSmo-MAP were injected on both the reference ﬂow
cell (Fc1), and the measure ﬂow cell (Fc2) coupled to CPN (Fig. 3B).
Membrane preparations from yeasts that do not express hSmo-MAP
presented a binding level of 64 RU corresponding to non-speciﬁcbinding (Fig. 3B sensorgram A). This non-speciﬁc binding was
expected due to the high hydrophobicity of the CPN. The signal
recorded with membrane preparations from yeast expressing hSmo-
MAP reached 211 RU (Fig. 3B sensorgram B), indicating that hSmo
present in the yeast membrane interacted with the CPN. Membrane
fractions obtained from yeast expressing hSmo-MAP cultured in the
40-L fermentor exhibited a comparable binding level (214 RU)
(Fig. 3B sensorgram C).
Therefore, hSmo-MAP expressed on the yeast plasma mem-
brane is able to interact with its antagonist, meaning that we suc-
ceeded in large-scale production of human Smo in yeast in a native
conformation.3.3. Antagonist-binding properties of puriﬁed Smoothened
S. cerevisiae expressing hSmo-MAPwas grown using amedium/air
volume ratio of 1/7, at 18 °C until the OD600 was 7. Then the plasma
membrane fraction was prepared and the hSmo-MAP receptor was
solubilized with DDM, which is one of the most efﬁcient detergents
for hSmo solubilization [8]. Around 60% of hSmo-MAPwas solubilized.
The hSmo-MAP was fully puriﬁed using a calmodulin column
followed by an Ni–NTA column. The silver stained SDS-PAGE
presented in Fig. 4 clearly showed the presence of two bands between
90 and 95 kDa, which were also visible on some western-blots. These
two bands could correspond to non-glycosylated and weakly
glycosylated forms of hSmo-MAP, respectively.
In order to compare the stability of hSmo-MAP in DDM and in the
ﬂuorinated surfactants (FSs) C6F13TAC, or C8F17TAC [12,13], DDMwas
exchangedwith FSs on the calmodulin resin during thewashing steps.
The resin was incubated with 5 volumes of buffer containing 2 mM of
C6F13TAC or C8F17TAC, slowly centrifuged and the supernatant
removed. This step was repeated 3 times before elution. hSmo-MAP
was eluted from the column by using a buffer containing 2 mM of
surfactant (DDM, C6F13TAC or C8F17TAC). This extensive wash using
batched resin is one of the most efﬁcient techniques for exchanging
detergents. Theoretical DDM concentration after exchange was 10
times bellow its CMC, suggesting that very few DDM molecules were
present in the hSmo/FS micelles. The western-blot analysis (Fig. 5A)
showed a band around 90 kDa of comparable intensity for hSmo-MAP
puriﬁed in DDM, C6F13TAC or C8F17TAC, suggesting that FSs main-
tained hSmo in a soluble state as well as DDM.
One day after puriﬁcation, the ability of puriﬁed hSmo-MAP to
bind the CPN was investigated. A quantity of hSmo-MAP puriﬁed in
DDM, C6F13TAC or C8F17TAC was injected onto both the reference
(Fc1) and the CPN-coupled (Fc2) ﬂow cells of the Biacore sensor chip,
and the difference between sensorgrams recorded on Fc2 and Fc1 was
reported (Fig. 5B). These results indicate that hSmo-MAP was able to
interact with its antagonist after puriﬁcation in DDM, but also in FSs.
The lower values of RU obtainedwith hSmo-MAP in FSs solution could
be due to a difference in refractive index between DDM and FSs, and/
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The fact that the speciﬁc refractive index increments (dñ/dc) of the
surfactants used to purify hSmo were different (0.14 for DDM and
0.08 for FSs) and that these surfactants may have an effect on the
binding response recorded by SPR, made it difﬁcult to compare
between the signals recorded in the presence of the different
surfactants. However, in order to clarify this point, different amounts
of cyclopamine were immobilized on Fc2 (11825 RU), Fc3 (8345 RU)
and Fc4 (2971 RU) of a new CM5 sensor chip, the Fc1 being the
reference ﬂow cell. Using buffer containing 2 mM DDM as running
buffer, we observed that the injection of buffer containing 2 mM of
C8F17TAC had a different effect depending on the amount of CPN-
coupled: it was positive in the absence of CPN (on Fc1) and negative in
the presence of CPN, the negative response being proportional to the
amount of coupled-CPN (Fig. S1A). This result suggests that each
surfactant interacts with the CPN coupled on the ﬂow cells and has a
different effect on the SPR response. To further consider surfactant
effects a second experiment was carried out in which hSmo puriﬁed in
DDM, C6F13TAC, C8F17TAC was diluted ten times in the DDM-
containing running buffer and injected on Fc1 and Fc2. The
sensorgrams resulting from the difference between signals recorded
on Fc2 and Fc1 were very different, suggesting that the surfactant
surrounding hSmo had an effect on the CPN and the SPR response.Fig. 5.DDM and ﬂuorinated surfactants preserved Smoothened integrity after puriﬁcation. A.
on SDS-PAGE and western-blotted with anti-HA antibodies. B. SPR measurements showing
MAP in DDM, in C8F17TAC or in C6F13TAC were injected over both Fc1 (reference ﬂow cell) an
in resonance units (RU) are the differences between sensorgrams recorded on Fc2 and Fc
responses of increasing concentrations of hSmo-MAP puriﬁed in DDM. 50 µL of increasing co
CPN-coupled Fc2. The differences between sensorgrams recorded on Fc2 and Fc1 at each hS
puriﬁed in DDM and in C8F17TAC. Sensorgrams recorded at increasing concentrations of hSm
calculated kinetic constants were reported.However, after dissociation time, recorded sensorgrams showed
similar RU values suggesting a recovery of DDM signals when FS-
puriﬁed Smo was diluted in DDM-containing buffer (Fig. S1B).
As a direct comparison of binding responses of hSmo puriﬁed in
the different surfactants was not possible, kinetic constants of hSmo/
CPN binding were determined. Increasing concentrations of hSmo
puriﬁed in DDM or FSs were injected on the ﬂow cells coupled to
different quantities of CPN and the sensorgrams recorded from the
difference between CPN-coupled Fc and the reference Fc1 were
superposed and analyzed using BiaEva software (Fig. 5C and D). The
afﬁnity constants of hSmo puriﬁed in DDM or C8F17TAC for its
antagonist were of the same order (5.8 nM and 2 nM respectively).
We also calculated from the Rmax values that the same amounts of
hSmo-MAP puriﬁed in DDM or in C8F17TAC (0.9 nmol) interactedwith
the CPN coupled to the sensor chip per mg of protein injected. These
values, which represent about 10% of the injected samples, were
calculated considering that the totality of the injected sample could
interact with the cyclopamine coupled to the sensor chip. However,
since the experiments were carried out with a continuous ﬂow, it was
impossible to know the volume of sample that was really in contact
with the cyclopamine. Unfortunately, the technique used did not
permit calculation of the number of active receptors, but just allowed
us to compare the amount of hSmo that interacted with cyclopaminehSmo-MAP puriﬁed in DDM (lane 1), C8F17TAC (lane 2) or C6F13TAC (lane 3) was loaded
that puriﬁed hSmo-MAP-bound to its antagonist, cyclopamine. 40 μL of puriﬁed hSmo-
d Fc2 (on which CPNwas immobilized by amine-coupling). The SPR responses reported
1, and correspond to the speciﬁc binding of hSmo-MAP on immobilized CPN. C. SPR
ncentrations of hSmo-MAP puriﬁed in DDM were injected over both reference Fc1 and
mo-MAP concentration are presented. D. CPN-binding kinetic constants for hSmo-MAP
o-MAP puriﬁed in DDM and in C8F17TAC were analyzed using BiaEva software and the
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that the samples injected onto the sensor chip were puriﬁed on the
calmodulin column and only gave a purity yield of about 60 to 70%, the
amount of active hSmo after puriﬁcation in DDM and in C8F17TAC
should be clearly higher than 10%.
3.4. Smoothened stability in solution
To compare the stability of puriﬁed detergent solubilized hSmo
receptor, we developed two stability assays based on SPR.
Time-dependent stability was determined from SPR binding
assays 10, 20 and 30 days after puriﬁcation in the different surfactants
with hSmo-MAP samples kept at 4 °C. Results showed that 1 month
after puriﬁcation, 45% of the initial hSmo still bound to the CPN in
DDM, and that this value was slightly higher in FSs (55% and 50% for
C6F13TAC and C8F17TAC respectively) (Fig. 6A). Our results indicated
that FSs were at least as efﬁcient as DDM in maintaining hSmo in
solution and in preserving hSmo–cyclopamine binding over time after
puriﬁcation.
The thermostability of hSmo-MAP puriﬁed in DDM and in FSs was
determined from SPR binding assays on hSmo-MAP incubated for
30 min at increasing temperatures ranging from 10 to 70 °C prior to
injection on the reference (Fc1) and the CPN-coupled (Fc2) ﬂow cells
of the Biacore sensor chip. The difference between sensorgrams
recorded on Fc2 and Fc1 was reported, giving the binding level for
each sample. Themaximal level of binding was determined on control
samples kept on ice. The percentage of remaining native receptors
was determined by comparing the amount of binding (in RU) after
heating with its unheated control (Fig. 6B). The apparent Tm, deﬁned
as the temperature at which 50% of the binding activity remained after
a 30-min incubation was calculated and reported. The hSmo-MAP in
DDM showed apparent Tm values of 40.7±2.3 °C. The apparent Tm inFig. 6. Smoothened stability in solution. A. Time-dependent stability of hSmo-MAP in
different surfactants. SPR responses were recorded 10, 20 and 30 days after puriﬁcation,
samples being kept at 4 °C. Remaining hSmo-MAP binding is represented as
percentages of the initial binding recorded 1 day after puriﬁcation. B. Thermostability
of puriﬁed hSmo-MAP. Samples of hSmo-MAP puriﬁed in DDM, C6F13TAC, or C8F17TAC
were heated for 30 min at increasing temperatures and injected on the Biacore sensor
chip to determine remaining hSmo-MAP binding activity, which was normalized
against the unheated control in each surfactant (100%). Data points are from duplicate
measurements and are representative of at least two independent experiments.
Apparent Tm values determined from the curves by nonlinear regression are indicated.C6F13TAC was lower (33.6±2.4 °C) than that in DDM, whereas the Tm
was shifted to 45.1±0.8 °C when hSmo-MAP was puriﬁed in
C8F17TAC.
Samples of hSmo-MAP puriﬁed in DDM, C8F17TAC and C6F13TAC
heated at increasing temperatures were mixed with loading buffer,
loaded on SDS-PAGE and western-blotted with anti-HA antibodies
(Fig. S2A). The western-blots showed that heating Smo did not induce
the appearance of new bands, suggesting that the loss of antagonist-
binding was not due to proteolysis. The band at 90 kDa was quantiﬁed
using Image J software and the percentage of remaining Smo at
90 kDa was plotted as a function of the temperature using Origin
software (Fig. S2B). For hSmo-MAP puriﬁed in DDM, the 90-kDa band
began to decrease at 40 °C, the Tm value being around 60 °C. For
hSmo-MAP in C8F17TAC, the 90-kDa band decreased by 20% at 20 °C,
was stable until 40 °C, and then decreased as for Smo in DDM with a
Tm value around 60 °C. These data suggest that the 20% decrease
observed at 20 °C in the antagonist-binding activity could be due to a
precipitation of Smo: it is possible that some of the Smo proteins did
not get enough C8F17TAC molecules to stabilize them. This could also
explain why the thermal transition was less cooperative in C8F17TAC
than in DDM. For hSmo-MAP puriﬁed in C6F13TAC, the Tm value
calculated from the intensity of the 90-kDa band was around 35 °C,
which was in good agreement with the Tm value calculated from
the antagonist-binding activity. These data suggest that the loss of
antagonist-binding after heating could be due to a progressive un-
folding followed by the precipitation of Smo in DDM and in C8F17TAC,
and to a more rapid precipitation in C6F13TAC.
SPR and western-blot analyses clearly indicated that hSmo-MAP
was at least as stable in the FS C8F17TAC as in the classical detergent
DDM, and less stable in C6F13TAC. The 12 °C shift in thermostability
between the two FSs could be due to the length of the ﬂuorocarbon
chain, which is longer for the C8F17TAC and would better protect
membrane proteins.
3.5. Characterization of the Smoothened mutant G435R
This mutant is the result of an error introduced during the PCR
carried out to modify the 5′ and 3′ extremities of hSmo cDNA for
cloning into the YEpPMA-MAP expression vector. The guanine in
position 1303 was substituted for adenine giving an arginine instead
of a glycine in position 435 of the third intracellular loop of hSmo.
Yeasts expressing hSmo-MAP or hSmoG435R-MAP were grown in
the same conditions, membrane proteins were prepared and loaded
on SDS-PAGE for western-blotting with anti-HA antibodies (Fig. 7A).
The ﬁrst observation was that, in the line where membranes prepared
from yeast expressing hSmoG435R-MAP were loaded, anti-HA anti-
bodies did not detect a band at 90 kDa as for hSmo-MAP but only the
band at 65 kDa. The second observation was that the densitometric
measure of the 65-kDa band corresponding to hSmoG435R-MAP was
2.5 times that of the 90-kDa corresponding to hSmo-MAP. Using the
puriﬁed MAP peptide as a standard, we could estimate that 120 pmol
of hSmoG435R-MAP was produced per mg of membrane proteins,
which corresponded to 360 μg/L of yeast culture. The western-blot
presented in Fig. 7A also shows that the 90-kDa band disappeared
after heating at 95 °C in the loading buffer whereas the 65-kDa band
was not affected by heating. This suggests that the 90-kDa protein and
the 65-kDa protein have differences in their folding. Membrane
preparations from yeast expressing hSmo-MAP and yeast expressing
hSmo-G435R-MAP were loaded on a native gel and the western-blot
revealed with anti-HA antibodies showed that both proteins migrated
identically on this native gel, with a stronger signal for hSmoG435R-
MAP than for hSmo-MAP (Fig. 7B). Moreover, we carried out
digestions with increasing amounts of trypsine on puriﬁed hSmo-
MAP and hSmoG435R-MAP. The western-blot analysis showed that
trypsine did not enhance the 65-kDa band for hSmo-MAP but
produced only one C-terminal fragment around 35 kDa both with
Fig. 7. Expression of the G435R-mutant Smoothened. A. Plasma membranes prepared from yeasts expressing hSmoG435R-MAP (lanes 1 and 2) or hSmo-MAP (lanes 3 and 4). 80 μg
of membranes were heated for 2 min at 95 °C in loading buffer (lanes 2 and 4) or not (lanes 1 and 3) and loaded on SDS-PAGE, western-blotted and probed with anti-HA antibodies.
Arrows indicate the 90-kDa and the 65-kDa bands. B. Membranes prepared from yeasts expressing hSmo-MAP (lane 1) or hSmoG435R-MAP (lane 2) were loaded on a native gel,
western-blotted and probed with anti-HA antibodies. C. Coomassie blue stained gel of puriﬁed hSmoG435R-MAP. hSmoG435R-MAPwas puriﬁed in DDM onNi/NTA and streptavidin
columns successively, loaded on a SDS-PAGE and stained by Coomassie blue. The 65-kDa band indicated by an arrow was cut for mass spectrometry analysis. D. Amino-acid
sequence of human Smoothened (Homo sapiens) (from NP 005622; NCBI, http://www.ncbi.nlm.nih.gov.gate1.inist.fr). Peptides detected by mass spectrometry from the cut 65-kDa
band are in bold and underlined. They occur in the N-terminal domain, the ﬁrst extracellular loop, the 2nd intracellular loop, the 3rd intracellular loop, the 3rd extracellular loop, the
7th TMS and the C-terminal domain of the human receptor Smoothened. E. CPN-binding of membrane-bound G435R-mutant Smoothened measured by SPR. 50 μL of membranes
(100 μg/mL) prepared from control yeasts that do not express hSmo, from yeasts expressing hSmo-MAP, and from yeasts expressing hSmoG435R-MAP were injected over both the
reference ﬂow cell Fc1 and the CPN-coupled ﬂow cell Fc2 of a CM5 sensor chip. The sensorgrams presented show the difference between signals recorded on Fc2 and Fc1.
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kDa band observed on hSmo-MAP western-blot does not correspond
to a proteolysed form of Smo. Taken together, these observations
suggested that the mutant receptor hSmo-G435R-MAP could have a
more stable conformation making it less denatured by SDS which
could explain the faster running on SDS-PAGE.
However, in order to verify that the special migration of
hSmoG435R-MAP was not due to a truncated protein, hSmoG435R-
MAP was puriﬁed in DDM on an Ni/NTA column followed by a
streptavidin column. The 65-kDa band observed on the Coomassie
blue stained SDS-PAGE (Fig. 7C) was cut and analyzed byMALDI-TOF–
TOF mass spectrometry. Several peptides were identiﬁed between the
amino acids number 66 and 575 (Fig. 7D). Moreover, the 65-kDa band
being detected by anti-HA antibodies on western-blots indicated that
the MAP sequence was present at the C-terminal extremity of mutant
Smo. The 65 N-terminus residues could have been truncated resulting
in 8 kDa deletion but this cannot explain the running at 65 kDa of the
protein. Therefore, the data suggested that the 65-kDa band would
correspond to the full-length MAP-tagged hSmoG435R protein and
would result from atypical running behavior.3.5.1. Antagonist-binding properties of the Smoothened mutant G435R
We tested the ability ofmembrane-boundhSmoG435R-MAP to bind
to the Smo antagonist cyclopamine by SPR studies. Membrane
preparations from yeast either expressing hSmo-MAP or hSmoG435R-
MAP, or from a control yeast strain that did not express hSmo, were
injected onto the reference ﬂow cell (Fc1) and the measure ﬂow cell
(Fc2) coupled to the CPN.We observed thatmembranes prepared from
yeast expressinghSmoG435R-MAPgavea comparablebinding response
to membranes prepared from yeast expressing hSmo-MAP (Fig. 7E),
indicating that themutation G435R did not prevent antagonist-binding.
However, we expected a higher binding activity with hSmoG435R-
MAP-bound membranes since western-blotting suggested that the
mutant receptor was more strongly expressed than the wild-type.
3.5.2. Thermostability of the Smoothened mutant G435R in solution
We also studied the thermostability of hSmoG435R-MAP after
puriﬁcation in different surfactants, as was done for the wild-type
receptor (Fig. 8). Tm values obtained for hSmoG435R-MAP in DDM
were relatively close to that of hSmo-MAP (38±1.3 °C and 40.7±
2.3 °C respectively, Table 1). In C8F17TAC, however, we obtained Tm
Fig. 8. Thermostability of the puriﬁed G435R-mutant Smoothened. Samples of
hSmoG435R-MAP puriﬁed in DDM or C8F17TAC were heated for 30 min at increasing
temperatures and injected on the Biacore sensor chip to determine remaining binding
activity which was normalized against the unheated control in each surfactant (100%).
Data points are from duplicate measurements and are representative of at least two
independent experiments. Apparent Tm values were determined from the curves by
nonlinear regression.
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higher than Tm values obtained with hSmo-MAP in the same
surfactant (Table 1).
3.5.3. Activation of the Smoothened mutant G435R by Hedgehog
To ﬁnd out if the mutation G435R had an effect on the localization
of hSmo in response to Hedgehog, we performed surface immuno-
ﬂuorescence labeling on Drosophila Schneider 2 (S2) cells transiently
transfected with pAc-hSmo-MAP or pAc-hSmoG435R-MAP. The cells
were incubated with a rhodamine ﬂuorescent polyclonal antibody
raised against the 300 last amino acids of hSmo that recognized the
3rd extracellular loop of hSmo, and analyzed by confocal ﬂuorescent
microscopy. In agreement with our previously published results [9],
hSmo-MAP expressed in S2 cells was present on the plasma mem-
brane in the absence of Hh, and treatment of cells with Hh enriched
hSmo-MAP at the cell surface. Cell surface immunoﬂuorescent
labeling on hSmoG435R-MAP gave comparable results (Fig. 9A). The
amount of hSmoG435R-MAP present on the plasmamembrane before
Hh treatment was slightly lower than that for the wild-type, and
incubation of the cells with Hh increased the amount of hSmoG435R-
MAP on the plasma membrane 1.8 times instead of 1.5 times for the
wild-type (Fig. 9B).
4. Discussion
This study reports the large-scale expression, the puriﬁcation, and
the stabilization of the human GPCR Smoothened.Table 1
Tm values obtained for Smoothened wild type and G435R puriﬁed in DDM and
C8F17TAC. hSmo-MAP and hSmoG435R-MAP puriﬁed in DDM or C8F17TAC were heated
30 min at increasing temperatures and injected on the Biacore sensor chip to determine
remaining CPN binding activity which was normalized against the unheated control in
each surfactant (100%). Apparent Tm values were determined from thermostability
curves by nonlinear regression using Origin software.
Tm (°C)
hSmo-MAP hSmoG435R-MAP
DDM 40.7±2.3 38±1.3
C8F17TAC 45.1±0.8 51±1.5hSmo was expressed in the yeast S. cerevisiae with a multitag
afﬁnity puriﬁcation sequence of 165 amino acids fused at its C-
terminus. We showed in a previous study that hSmo-MAP expressed
in Drosophila Schneider 2 cells was inhibited by Patched in the
absence of Hh, stabilized at the surface of Drosophila cells in response
to Hh, and bound its antagonist cyclopamine as wild-type Smo [9],
meaning that the presence of the MAP sequence at the C-terminal
extremity of hSmo did not affect its activity. We estimated the
amount of MAP-tagged hSmo expressed on the plasma membrane of
the yeast S. cerevisiae to be around 150 μg of hSmo per L of yeast
culture, 20 to 50 pmol/mg of membrane proteins (meaning 50 to
100% of expressed hSmo) being able to bind cyclopamine. The latter is
a steroidal alkaloid extracted from the lily corn plant Veratrum
californicum that binds to the heptahelical bundle of mammalian
Smoothened, inhibiting the Hedgehog pathway [15], and does not
recognize Drosophila Smoothened. The expression level obtained is
not very high, but the 40-L fermentor production should be sufﬁcient
to perform biochemical and structural studies.
Surface plasmon resonance experiments were developed to
measure the interaction of hSmowith its antagonist, the cyclopamine,
covalently coupled to the sensor chip ﬂow cells. The binding of
membrane-bound hSmo-MAP to the cyclopamine indicated that
hSmo-MAP was expressed in a native conformational state in
S. cerevisiae grown in 2-L ﬂasks as well as in a 40-L fermentor. After
solubilization of hSmo-MAP from the membrane with the non-ionic
detergent DDM, we showed that hSmo-MAP could be puriﬁed in DDM
but also in ﬂuorinated surfactants using the afﬁnity tags present in the
MAP. Solubilization of membrane proteins often results in destabili-
zation, unfolding and subsequent aggregation. To investigate whether
puriﬁed hSmo-MAP kept its integrity and antagonist-binding ability
in surfactant solution, we performed SPR experiments and checked
time-dependent stability and thermostability. Biacore SPR experi-
ments showed that DDM preserved the ability of hSmo-MAP to
interact with its antagonist in solution at 4 °C for at least 1 month after
puriﬁcation. Thermostability assays allowed the melting temperature
(Tm) of hSmo-MAP in DDM to be estimated at about 40 °C, indicating
that hSmo is a relatively stable GPCR.
Because ﬂuorinated surfactants (FSs) have been shown to be less
aggressive towards certainmembraneproteins thanclassical detergents
[16,17], and because we have recently shown that these FSs preserved
the integrity and stability of human Patched, the other membrane
protein of the Hedgehog pathway [18], we studied the ability of FSs to
maintain hSmo-MAP integrity in solution. Our results showed that the
amount of hSmo-MAP obtained after puriﬁcation was comparable in
DDMand in FSs. However, the cyclopamine-binding signals observedby
SPRwere lower in FSs than in DDM. It has to be recalled that FSs possess
the samegeneral structure as classical detergents, i.e. a hydrophilic head
group and a hydrophobic tail, but the latter, rather than being a
hydrogenated aliphatic chain, is a ﬂuorocarbon chain [12,13]. The
polymer head of FSs is much more hydrophilic than that of DDM. This
could induce a repulsion effect between hSmo/FS micelles and the
highly hydrophobic cyclopamine bound to the ﬂow cell surface, which
could be compared to the brush effect observed with the stealth
liposomes [19]. This property could explain the lower binding of hSmo-
MAP with the cyclopamine in the presence of FSs. Kinetic analysis
allowed us to calculate that afﬁnity for cyclopamine was of the same
order in DDM or in C8F17TAC and comparable to the values obtained for
Smo in membrane preparations, and that the same amount of active
Smo was present in DDM or in C8F17TAC solution. The amount of
remaining binding activity 1 month after puriﬁcation in FSs suggested
that FSs were at least as efﬁcient as the classical detergent DDM in
maintaining hSmo-MAP in solution and in preserving hSmo–cyclopa-
mine binding. It is noticeable that the apparent Tm of hSmo-MAP in
C8F17TACwas 4 to 5 °C higher than that of hSmo-MAP inDDM. This shift
in Tm could be important for crystallization, as reported for the β1
adrenergic receptor [20] and the adenosine receptor [21].
Fig. 9. Activation of the G435R-mutant Smoothened by Hedgehog in the Drosophila Schneider 2 cells. Drosophila S2 cells transfected with 0.5 μg of pAc-hSmo-MAP or pAc-
hSmoG435R-MAP, treated (+) or not (−) with Hh-conditioned medium, were incubated on ice for 1 h with rabbit anti-hSmo antibody and 30 min with a rhodamine ﬂuorescent
secondary antibody. A. The rhodamine ﬂuorescence corresponding to the hSmo amount at the cell surface was analyzed by confocal microscopy with an objective ×63. A. B. The
intensity of rhodamine ﬂuorescence of ∼20 hSmo-MAP or hSmoG435R-MAP-expressing cells, normalized by cell area, was quantiﬁed using Image J software (arbitrary units; AU)
and reported in the histogram.
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mutant [22], and the use of a mutant that improves thermostabiliza-
tion and/or conformational homogeneity of the receptor seems to be
a good strategy for the structure determination of GPCRs [21]. One of
the hSmo mutant clones generated by PCR, in which a neutral glycine
residuewas replaced by a positively charged arginine residue, showed
a higher expression level than the wild-type hSmo in the yeast S.
cerevisiae. Moreover, this mutation was located in the third intracel-
lular loop of hSmo which had been shown to be very important for
Smoothened activity [23]. Therefore, expecting that this mutation
could improve hSmo stability, we decided to further characterize this
mutant and to study its thermostability. Surprisingly, this mutant
protein ran only under the 65-kDa form instead of the expected 90-
kDa major form and the 65-kDa weak band obtained with the wild-
type receptor on SDS-PAGE. However, mass spectrometry analysis
and a running proﬁle on native gel strongly suggested that
hSmoG435R-MAP was expressed in S. cerevisiae along its full-length.
The fact that the 65-kDa band did not disappear after heating in
loading buffer, contrary to the 90-kDa band, suggested that the
running behavior of hSmoG435R-MAP could be due to a more stable
conformation, less denatured by SDS-containing loading buffer. It
must also be mentioned that membrane proteins frequently run at
lower apparent molecular weight than their theoretical value due to
their high hydrophobicity [24,25]. Quantiﬁcation of hSmoG435R-
MAP on western-blot suggested that the level of expression of
hSmoG435R-MAP was 2.5 times higher than that of hSmo-MAP;
however, the cyclopamine-binding properties were comparable
to those of hSmo-MAP. If the denatured state of hSmoG435R-MAP
is different from that of hSmo-MAP, we cannot exclude a higher
reactivity of anti-HA antibodies with themutant protein thanwith the
wild-type, which could explain the higher level of expression
estimated. However, if G435R mutation had an effect on Smoothened
conformation, surface immunoﬂuorescent labeling showed that this
mutation did not affect Smoothened enrichment on theDrosophila cell
plasmamembrane in response to Hh activation, which is in agreement
with our previous data [9] and other studies [26].Thermostability of hSmoG435R-MAP in the classical detergent
dodecyl maltoside is comparable to that of hSmo-MAP with a Tm
of about 40 °C. However, in the ﬂuorinated surfactant C8F17TAC,
the thermostability of the mutant is higher than that of wild-type
receptor in the same surfactant, and reached 51 °C. These results
showed that the FS C8F17TAC increased the thermostability of
hSmoG435R-MAP by about 13 °C compared to dodecyl maltoside,
and conﬁrmed the stabilizing effect of the FS C8F17TAC on hSmo. The
mutation G435R neither affected antagonist-binding nor the response
of hSmo to Hh activation, but strongly stabilized the receptor in the
ﬂuorinated surfactant C8F17TAC solution. There is a synergistic effect
of the mutation G435R and the FS C8F17TAC on the stability of
Smoothened in solution that could be very helpful for crystallization
and structural characterization [21,27].
In summary, this is the ﬁrst study reporting conditions in which
the human receptor Smoothened is in a native stable conformational
state and interacts with its antagonist cyclopamine in solution after
puriﬁcation. The apparent melting temperatures obtained for hSmo in
the classical detergent DDM and in the ﬂuorinated surfactant
C8F17TAC suggest that Smo is relatively stable in solution. Moreover,
the results obtained with a mutant form of Smoothened presenting
the replacement of a glycine by an arginine in the third intracellular
loop showed that this mutation strongly stabilized the receptor in the
ﬂuorinated surfactant C8F17TAC solution.
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